Please ensure Javascript is enabled for purposes of website accessibility

Moderna Plans to Raise $1.25 Billion in a Secondary Offering

By Brian Orelli, PhD – May 18, 2020 at 9:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the COVID-19 vaccine drugmaker are up 339% this year.

Taking advantage of its monstrous 339% share price gain this year, including today's 20% gain on promising phase 1 data for its COVID-19 vaccine mRNA-1273, Moderna (MRNA -0.55%) plans to raise a whopping $1.25 billion selling shares in a secondary offering. The biotech expects to give the underwriters a 30-day option to purchase up to an additional $187.5 million in shares, so the total amount raised could be in excess of $1.4 billion.

At that level, this will be one of the largest secondary offerings for a biotech company in recent memory -- perhaps ever. There are some months when the entire industry doesn't raise $1.4 billion combined. Typically, companies needing to rise that much capital would go to the debt market and sell bonds or convertible notes, so they didn't have to dilute shareholders.

But these aren't typical times, and Moderna isn't a typical company. The biotech sports a nearly $30 billion market cap despite not having any drugs on the market. Taking out debt doesn't make much sense if you don't have any meaningful revenue coming in to put toward the interest payments.

Using its stock to raise capital at this lofty valuation, on the other hand, is a smart move. It'll dilute shareholders, but only by about 5%, and the hope for shareholders is that the valuation will go even higher if Moderna can get mRNA-1273 through the clinical trial process and onto the market.

Pen and magnifying glass on a balance sheet

Image source: Getty Images.

Moderna will need the large infusion of capital to help pay for larger phase 2 study (expected to begin shortly) and phase 3 study (expected to start in July) as well as for ramping up production of the vaccine. The biotech ended the first quarter with $1.7 billion in the bank and had another $0.7 billion in grants and awards that could potentially be spent on the vaccine and the rest of Moderna's pipeline.

The price for the shares being sold in the offering hadn't been disclosed at the time of publication.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$123.64 (-0.55%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.